LOGO

You are here: 

  • Home

 


News from members

  • DiaGenic and Ferrer inCode Sign Distribution Agreement

    DiaGenic ASA and Ferrer inCode have signed a distribution agreement for the blood-based ADtect test for early diagnosis of Alzheimer’s disease covering a total of 32 countries. The agreement gives Ferrer inCode the exclusive right to sell and market ADtect initially in Germany, Belgium, the Netherlands, Luxemburg, France, Italy, Spain and Portugal followed by Latin America.

    >> Read more21.01.10

  • Strong anti-tumour response observed by PCI Biotech

    PCI Biotech has completed the treatment of the second dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients. "We are very excited by the positive results", says PCI Biotech CEO Per Walday.

     

    >> Read more21.01.10

  • Nutri Pharma ASA launches offer for Bionor Immuno AS

    Nutri Pharma ASA has submitted a voluntary exchange offer for all outstanding shares in Bionor Immuno AS. The shareholders of Bionor will be offered 1 Nutri Pharma share per 2 shares in Bionor Immuno AS. -- We are very excited about the prospects, says Trond Syvertsen (picture), CEO of Nutri Pharma ASA.

    >> Read more19.01.10

  • Algeta and IFE agree to collaborate

    Algeta ASA, the cancer therapeutics company, and the Institute for Energy Technology (IFE), the international research institute for energy and nuclear technology based in Oslo, have agreed to collaborate for the manufacture and supply of Alpharadin for future commercial use and clinical trials.

    >> Read more18.01.10

  • NorDiags share offering heavily oversubscribed

    NorDiag has received subscriptions for approximately 19,2 million shares in the subsequent offering closed today. This represents approximately 240 percent of the total number of offered shares.  - We are most satisfied with this oversubscription, which we interpret as shareholders confidence in our recent performance and strategy going forward, says CEO Mårten Wigstøl (picture).

    >> Read more13.01.10

  • Abelia og NBA støtter norsk deltakelse i ELIXIR

     Abelia og Norsk Biotekforum (NBA) støtter arbeidet med å få på plass en norsk node i Elixir og ber Forskningsrådet legge til rette for et møte for å orientere om planene, fremgår det av et brev til Norges forskningsråd. Elixir er den europeiske life science-infrastrukturen for biologisk informasjon.

    >> Read more23.12.09

  • FDA Advisory Committee recommends Hexvix

    The FDAs Oncologic Drugs Advisory Committee (ODAC) has recommended Photocure's pharmaceutical product Hexvix as an adjunct to white light cystoscopy in the detection of non-muscle invasive papillary cancer of the bladder.

    >> Read more18.12.09

  • Superba Krill Oil ready for the European market

    Aker BioMarine has been notified by the Finnish Food Safety Authority that Superba™ Krill Oil is now approved as Novel Food in the European Union. Consequently, Superba™ Krill Oil can be sold in all countries within the European Union.

    >> Read more17.12.09

  • Algeta ASA starts randomizing patients

    Algeta ASA, the cancer therapeutics company, announces that the Tulane Cancer Center has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant prostate cancer (CRPC) that has metastasized to the skeleton.

    >> Read more11.12.09

  • Biotec Pharmacon realigns strategy and reduces workforce

    Biotec Pharmacon has decided to reduce the workforce within the parent company by 20 people out of a total of 35, to reflect a reduced activity level following the negative outcome of the phase III studies with SBG for diabetic ulcer.

    >> Read more11.12.09

Showing from 1 to 10 of total 66 articles

Events

    >> All events

 

 


 

Norwegian Bioindustry Association

Middelthuns gt. 27, Postboks 7072 Majorstuen, NO-0306 Oslo Tel: +47 23 08 88 00 / +47 23 08 88 18 / +47 91 10 54 91 Email: biotek@norskindustri.no Fax: +47 23 08 88 98